UK Markets closed

Genfit SA (GNFT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3500-0.0600 (-1.76%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.4100
Open3.4200
Bid3.3500 x 800
Ask3.8700 x 3200
Day's range3.3500 - 3.4300
52-week range3.2600 - 7.1900
Volume19,365
Avg. volume7,025
Market cap153.701M
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-3.1090
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

    Lille, France; Cambridge, MA; November 18, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique

  • Globe Newswire

    GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program

    Lille, France; Cambridge, MA; November 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program. The open-label, non-randomized, 2-center, repeated-dose, parallel-group study will provide preliminary insight into NTZ pharmacokinetics (PK) and safe

  • Globe Newswire

    GENFIT: Third Quarter 2021 Financial Information

    Cash and cash equivalents: €91.5 million as of September 30, 2021 Lille, France; Cambridge, MA; November 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2021 and revenues for the first nine months of 20211. Cash Position As of September 30, 2021, the Company’s cash and cash equivalents amounted to €91.5 million compared